Recently Updated
Bill Gates - Makes Cannabis a Medicine Last Updated on 2017-09-20 13:55:09 Forbes  |  by Janet Burns For The Past 12 Years, Bill Gates Did What The FDA Won't: He Made Cannabis A Medicine In 2005, Bill Gates had a life changing meeting with veterans of the War in Afghanistan through the Bill & Melinda Gates Foundation. Ever since hearing their stories that day, Gates has set out to find the safest, most effective form of medicinal cannabis for treating the conditions of former solders and others, and to bring that product to the masses. After 12 years of non-stop research and advocacy, those goals are finally in hand..... Gates, whose company recovers CBD from cannabis plants using the 'green method' of supercritical fluid extraction (SFE) with C02 ... Cannabinoid, or CBD, is a miracle product that everyone has been using to Completete various conditions, including chronic pain, anxiety, nausea, rheumatoid arthritis,... More »
Hyperbaric Oxygen Therapy Effects on Diabeties Last Updated on 2017-08-24 18:42:23 Source Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=Hyperbaric+oxygen+therapy+of+olfactory+dysfunction+in+diabetic+neuropathy+with+type+2+diabetes+mellitus+and+a+new+definition+Diabetic+Olfactopathy. Rhinology. 2016 May 12. [Epub ahead of print] Veyseller B1, Dogan R2, Yenigun A2, Aksoy F2, Tugrul S2, Dogan EE3, Ozturan O2.   Hyperbaric Oxygen therapy is recommended as an adjuvant therapy for diabetic neuropathy. To investigate olfactory dysfunction and show the effectiveness of hyperbaric oxygen treatment in patients with type 2 diabetic neuropathy. Patients diagnosed with Type 2 DM and diabetic neuropathy were included in the group 1. Patients of Group 1 were administered with a hyperbaric oxygen therapy for 30 sessions and patients who returned for a check up following 30 sessions were incorporated into the Group 2. Healthy volunteers with no medical... More »
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Last Updated on 2017-08-24 18:19:54 US National Library of Medicine - National Institutes of Health. see: https://www.ncbi.nlm.nih.gov/pubmed/17714746 Neuropharmacology. 2008 Jan;54(1):244-9. Epub 2007 Jul 17. Weiss L1, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R.   We have previously reported that cannabidiol (CBD) lowers the incidence of diabetes in young non-obese diabetes-prone (NOD) female mice. In the present study we show that administration of CBD to 11-14 week old female NOD mice, which are either in a latent diabetes stage or with initial symptoms of diabetes, ameliorates the manifestations of the disease. Diabetes was diagnosed in only 32% of the mice in the CBD-treated group, compared to 86% and 100% in the emulsifier-treated and untreated groups, respectively. In addition, the level of the proinflammatory cytokine IL-12 produced by splenocytes was significantly reduced,... More »
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications Last Updated on 2017-08-24 18:17:34 The American Journal of Pathology - Cellular and Molecular Biology of Disease see: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349875/ Oxidative stress and inflammation play critical roles in the development of diabetes and its complications. Recent studies provided compelling evidence that the newly discovered lipid signaling system (ie, the endocannabinoid system) may significantly influence reactive oxygen species production, inflammation, and subsequent tissue injury, in addition to its well-known metabolic effects and functions. The modulation of the activity of this system holds tremendous therapeutic potential in a wide range of diseases, ranging from cancer, pain, neurodegenerative, and cardiovascular diseases to obesity and metabolic syndrome, diabetes, and diabetic complications. This review focuses on the role of the endocannabinoid system in primary diabetes and its... More »
Role of the endocannabinoid system in diabetes and diabetic complications. Last Updated on 2017-08-24 18:13:54 Source Link: https://www.ncbi.nlm.nih.gov/pubmed/18194939 2007 Nov-Dec;13(7):790-804. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. Davis SN1, Perkins JM. Author information Abstract OBJECTIVE: To review the role of the endogenous cannabinoid system (ECS) in the peripheral and central regulation of food intake, appetite, and energy storage and discuss the potential for the ECS to be an important target for lowering cardiovascular risk. METHODS: Materials used for this article were identified through a MEDLINE search of the pertinent literature (1975 to present), including English-language randomized controlled, prospective, cohort, review, and observational studies. We summarize the available experimental and clinical data. RESULTS: The ECS is composed of two 7-transmembrane G protein-coupled cannabinoid... More »